26results about "Fibroblast growth factor" patented technology

This invention provides a thermostable hbFGF mutant and a method for its efficient expression in Escherichia coli. By mutating five amino acid sites of wild-type hbFGF (D15I / C78S / C96Y / S137P / K128N) to improve thermostability, optimizing molecular design, constructing an expression vector, and transforming the expression strain of Escherichia coli, efficient and soluble expression of hbFGF in Escherichia coli is achieved.

Provided is use of an FGF21 / GLP-1 fusion protein in the preparation of a drug for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion protein can effectively treat at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. Especially, the fusion protein can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in a subject, or can improve at least one of adiponectin, insulin sensitivity, and β cell function in the subject.

This invention relates to a fusion protein comprising a GLP-1 polypeptide and an FGF21 polypeptide separated by a spacer. The invention also relates to a fusion compound comprising the fusion protein and at least one substituent. Furthermore, the invention relates to pharmaceutical applications of the fusion compound.

To provide human colonic organoids in vitro, usable for determining the efficacy and / or toxicity of potential therapeutics for a disease selected from the group consisting of colitis, colon cancer, polyposis syndrome and / or irritable bowel syndrome.SOLUTION: The disclosure provides a human colonic organoid (HCO), where the human colonic organoid comprises epithelium and mesenchyme and expresses SATB2, MUC2 and / or MUC5B.SELECTED DRAWING: Figure 1A

According to various aspects of this disclosure, the present disclosure relates to a method for treating or reducing pulmonary inflammation and / or pulmonary fibrosis in a subject in need thereof comprising intramuscularly administering to the subject a recombinant adeno-associated virus (rAAV) vector. In some aspects, the rAAV vector comprises a vector genome and an AAV capsid (e.g., an AAV1 serotype). In some aspects, the vector genome comprises AAV inverted terminal repeats (ITRs) flanking an expression construct comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or functional fragment thereof operably linked to a ubiquitous promoter.

The application provides a myocardial infarction diagnostic marker and a myocardial infarction therapeutic drug, and belongs to the technical field of in-vitro diagnosis and biological medicine, in particular, the myocardial infarction diagnostic marker comprises FGF18 protein or a protein mutant with at least 90% sequence identity with the FGF18 protein, and the amino acid sequence of the FGF18 protein is shown as SEQ ID No. 1. The myocardial infarction therapeutic drug comprises FGF18 protein or an FGF18 protein expression promoter. The application firstly proposes FGF18 as the myocardial infarction diagnostic marker and the myocardial infarction therapeutic drug, and provides a new thought for the detection and treatment of myocardial infarction.

Dry eye disease (DED) is an example of a disease with a significant unmet need and a pressing need for treatment. Unfortunately, current drug therapies are ineffective for many dry eye patients, and the disease often progresses. Therefore, there is a need for novel, less aggressive, and better treatment options for dry eye disease, as described in this application. Methods for treating, repairing, or restoring diseases, disorders, or injuries associated with dry eye disease, wound healing, and osteoarthritis are described herein. Methods for generating megakaryocyte derivatives are also described herein.

Disclosed is an engineered exosome, comprising (a) an FGF21 polypeptide, fused to a first anchoring polypeptide, (b) an IL-27 polypeptide, fused to a second anchoring polypeptide, and (c) an activin receptor type II polypeptide, fused to a third anchoring polypeptide, wherein (a), (b) and (c) are anchored on a membrane of the exosome via the first, second and third anchoring polypeptide, respectively, and wherein the FGF21 polypeptide, the IL-27 polypeptide and the activin receptor type II polypeptide are exposed on an outer surface of the membrane of the exosome. Also disclosed are compositions, nucleic acid constructs, and uses of the exosome in treating metabolic disorders.

The invention relates to a viral expression construct and related viral vector and nucleic acid molecule and composition and to their use wherein said construct and vector are suitable for expression in a mammal and comprise a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) to be expressed in liver, adipose tissue and / or skeletal muscle.

GLP-1-Fc-FGF21 double-target fusion protein composition and its use. The composition comprises a GLP-1-Fc-FGF21 fusion protein and a buffer solution. In the composition, by adding the buffer solution, the formation of visible particles can be effectively controlled, the stability of the GLP-1-Fc-FGF21 fusion protein can be improved, and the shelf life of the product can be extended. The composition can be used to treat and / or prevent metabolic diseases such as diabetes, dyslipidemia, obesity, and diseases associated with fatty liver.

The present application relates to the application of Hu sheep FGF1 gene and its coded protein, and belongs to the field of biotechnology. The application of Hu sheep FGF1 gene and its coded protein in regulating the level of oxidative stress, cell apoptosis or cell proliferation of ovary granulosa cells. The present application first systematically identifies the CDS and protein sequence of sheep FGF1 gene, and analyzes its physical and chemical properties, post-translational modification sites, secondary and tertiary structures and systematic evolution relationship, which provides a molecular basis for revealing the role of the gene in oxidative stress and cell fate regulation. In addition, the disclosed sequence information and variation data are helpful for evaluating population genetic diversity, and have important scientific value for the protection, development and evolution research of animal genetic resources.

The present disclosure provides a technique for efficiently transferring a target foreign substance from outside a eukaryotic cell into at least a cytoplasm of the cell. A method for transferring a target foreign substance from outside a eukaryotic cell into at least a cytoplasm of the cell disclosed herein includes the steps of: (1) preparing a construct for transferring a foreign substance, the construct including a carrier peptide fragment including an amino acid sequence: RSRKYTSWYVALKRWPC (SEQ ID No.: 1), and the target foreign substance that is bonded to an N-terminus and / or a C-terminus of the carrier peptide fragment; (2) supplying the construct for transferring a foreign substance into a sample including a target eukaryotic cell; and (3) incubating the sample to which the construct for transferring a foreign substance has been supplied, thereby transferring the construct into the eukaryotic cell in the sample.

A fusion protein having a triple activity and a use thereof are provided. More specifically, a fusion protein has a triple biological activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and epidermal growth factor 21 (FGF21). It can be used for treating type 2 diabetes (T2D), obesity, and other diseases related to glucose and lipid metabolic abnormalities.

Disclosed herein are compositions and methods for treating arthritis (e.g., osteoarthritis or rheumatoid arthritis) in a subject. The methods provided herein include intra-articular administration to a subject in need thereof using a composition comprising one or more nucleic acids that collectively encode an interleukin-1 receptor antagonist (IL-1Ra) polypeptide and an FGF18 polypeptide. Adeno-associated virus (AAV) viral genomes and particles carrying such nucleic acids and uses thereof are further described.

This application provides a circular RNA encoding FGF21 and its use in treating diseases such as obesity, diabetes, or metabolic disorder-associated fatty liver disease (MAFLD) or steatohepatitis (MASH).

Provided is a novel use for a stem cell culture supernatant. Provided is a composition that contains a stem cell culture supernatant and that is for use in medical or cosmetic applications for a subject.

Compositions, methods and therapeutic regimens of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.

Provided herein are methods of engineering a cell line for reduced dependence on exogenous growth factor(s). In some embodiments, the method includes introducing into a cell one or more of: a polynucleotide comprising a coding sequence of a growth factor ligand; a polynucleotide comprising a coding sequence of a growth factor receptor; or a polynucleotide comprising a coding sequence of an activated downstream growth factor target, and culturing the cells in a cultivation infrastructure.

To provide a fusion protein containing an FGF21 mutant protein which has improved in vivo duration, protein stability and pharmacological effectiveness.SOLUTION: Provided is a fusion protein containing an FGF21 mutant protein and an Fc region of immunoglobulin. The fusion protein shows improved pharmacological effectiveness, in vivo duration and protein stability, and a pharmaceutical composition containing the fusion protein as an active ingredient can be effectively used as a therapeutic agent for diabetes mellitus, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.SELECTED DRAWING: Figure 5

An FGF21 polypeptide has one or more of the following properties: stable structure, long half-life, low immunogenicity, high biological activity, and enhanced glucose-lowering and lipid-lowering activities. A fusion protein or immunoconjugate includes the FGF21 polypeptide.

The present invention provides a thymic epithelial cell production method, the method including a step for culturing thymic epithelial progenitor cells for a long period of time. The present invention also provides a transplant therapeutic agent that includes thymic epithelial cells produced by the production method according to the present invention. The present invention further provides a T cell production method, the method including a feature of causing thymic epithelial cells produced by the production method according to the present invention to contact hematopoietic stem cells or any cells in the process of differentiation from hematopoietic stem cells to T cells.

The instant disclosure provides methods and compositions related to discovery of a long-acting FGF21 as a therapeutic target for treatment or prevention of neovascular eye diseases or disorders that are characterized by angiogenesis, or of vascular diseases of the eye. Therapeutic and / or prophylactic uses and compositions of long-acting FGF21 are described.

The present disclosure relates to methods of treating, preventing, or managing a cardiovascular and / or metabolic disorder in a human subject in need thereof by administering a human FGF21 protein variant, the metabolic disorder and / or cardiovascular disorder is selected from hypercholesterolemia, dyslipidemia, hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes, and obesity.

Provided herein are polynucleotides comprising at least two coding sequences for expression of coding sequences of interest in a cell and two transcriptional regulatory elements. The transcriptional regulatory elements may be tissue specific. Also provided are vectors, recombinant viral genomes, and recombinant virus compositions comprising said polynucleotides, as well as associated methods.

The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.